

Health Care Provider Perceptions of Current and Future Uptake of COVID-19 Vaccines in Europe and North America

Contact: Darrin Gilchrist dgilchrist@novavax.com

Anthony Marchese PhD,¹ Hadi Beyhaghi MD, PhD¹ Seth Toback MD,¹ Claudio Costantino MD, PhD² Presented by: Darrin Gilchrist¹

¹Novavax, Inc., Gaithersburg, MD, USA; ²Department of Health Promotion Sciences, Maternal and Infant Care, Internal Medicine and Excellence Specialties of the University of Palermo, Palermo, Italy

BACKGROUND

- Global COVID-19 booster vaccination rates remain low despite impassioned efforts by health care providers (HCPs) to support patient vaccination decisions
- Understanding HCP perceptions of COVID-19 vaccinations could help inform future vaccine policy strategies


RESEARCH OBJECTIVE

 Understand United Kingdom (UK), France (FRA), Germany (DEU), Italy (ITA), Canada (CAN), and United States (US) HCP perceptions toward COVID-19 vaccinations and the impact of these perceptions on interactions with patients

STUDY DESIGN

- We surveyed 1,062 UK, FRA, DEU, ITA, CAN, and US HCPs from May to July 2022.
- HCPs were defined by specialty and met specific eligibility criteria (Table 1)


Table 1. HCP Demographics



PCP=primary care physician, GP=general practitioner, NP=nurse practitioner, PA=physician assistant. *All HCPs were in practice for 2-35 years with ≥50% of professional time in direct patient care, personally managing ≥10 patients per month, personally managing patients at high risk for COVID-19 and were responsible for administering COVID-19 vaccines to patients.

RESULTS

Figure 1. HCP Attitudes to Patient Discussions on COVID-19 Vaccines



Question: Thinking about your discussions with patients on COVID-19 vaccines, please indicate your level of agreement with the statement shown above.

Insights

- Vaccine makers need to provide relevant data, such as real-world effectiveness and safety, to empower HCPs to educate patients and answer questions
- To support booster uptake, policy makers and health authorities who govern vaccine availability should consider the importance of appropriate COVID-19 vaccine choice to HCPs and their patients

booster COVID-19 vaccine brand

vaccinations (% HCPs would grant)

than what they received for their initial

